CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
ergocalciferol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01180946
NCT01180946N/ACompleted
CompareCT.gov

Vitamin D Deficiency in Adolescent Girls

Massachusetts General Hospital·interventional·Posted Aug 12, 2010·Updated Nov 5, 2013

In Brief

A clinical study evaluating ergocalciferol and placebo pill for Healthy and Vitamin D Deficiency. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Fibroblast growth factor 23 (FGF23) is a newly discovered hormone which regulates phosphate and vitamin D levels. In this study, we are looking at what the normal levels of FGF23 are in adolescent girls and how these levels vary with other hormonal measurements. We will also be looking at whether vitamin D supplementation in adolescents who are deficient in vitamin D alters the levels of FGF23 and other factors including insulin resistance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Vitamin D Deficiency
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 12, 2010
Enrollment StartSep 1, 2010
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.9 years ago

Interventions

ergocalciferoldietary

ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.

placebo pillother

placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion